Table 1 Baseline characteristics and clinical outcomes in neonates who received BMCFs and the control group
Characteristic* | Total (N = 156) | Received BMCFs (N = 75) | Control (N = 81) | OR (95% CI)‡ | Df ‡ | P † |
|---|---|---|---|---|---|---|
Gestational age (week) | 30.79 ± 2.47 | 31.00 ± 2.61 | 30.59 ± 2.34 | 151 | 0.18 | |
Birthweight (grams) | 1390.1 ± 314.4 | 1392.0 ± 325.6 | 1388.3 ± 305.7 | 154 | 0.85 | |
Sex | ||||||
Female | 69 (44.2%) | 34 (45.3%) | 35 (43.2%) | 1.09 (0.58, 2.05) | 0.79 | |
Male | 87 (55.8%) | 41 (54.7%) | 46 (56.8%) | |||
Delivery mode | ||||||
NVD | 33 (21.2%) | 10 (13.3%) | 23 (28.4%) | 2.58 (1.13, 5.87) | 0.02 | |
C-Section | 123 (78.8%) | 65 (86.7%) | 58 (71.6%) | |||
1-min Apgar | 8.0 [6.0–8.0] | 9.0 [8.0–10.0] | 9.0 [8.0–9.0] | 154 | 0.53 | |
5-min Apgar | 9.0 [8.0–9.75] | 9.0 [8.0–10.0] | 9.0 [8.0–9.0] | 154 | 0.42 | |
Gravidity | 2.0 [1.0–3.0] | 2.0 [1.0–3.0] | 2.0 [1.0–3.0] | 154 | 0.91 | |
Parity | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 154 | 0.52 | |
Use of infant formula | ||||||
Formula milk consumption | 20 (12.8%) | 6 (8.0%) | 14 (17.3%) | 0.42 (0.15, 1.15) | 0.08 | |
Formula milk consumption duration (day) | 17.4 ± 12.7 | 14.8 ± 11.4 | 18.5 ± 13.4 | 18 | 0.57 | |
In-hospital outcomes | ||||||
Hospital length of stay (day) | 28.0 ± 22.9 | 29.8 ± 23.8 | 26.3 ± 21.9 | 154 | 0.48 | |
Discharge weight (grams) | 1694.6 ± 212.6 | 1679.1 ± 195.2 | 1710.8 ± 229.7 | 135 | 0.60 | |
Mortality | 19 (12.2%) | 5 (6.7%) | 14 (17.3%) | 0.34 (0.12, 1.00) | 0.04 | |
Intubation period (day) | 3.6 ± 6.9 | 3.2 ± 7.1 | 4.0 ± 6.6 | 152 | 0.17 | |
NIV period (day) | 8.1 ± 10.9 | 9.4 ± 11.9 | 6.9 ± 9.7 | 153 | 0.21 | |
NEC | 11 (7.1%) | 4 (5.3%) | 7 (8.8%) | 0.59 (0.16, 2.09) | 0.41 | |
BPD | 24 (15.4%) | 14 (18.7%) | 10 (12.3%) | 1.63 (0.67, 3.93) | 0.27 | |
ROP | 41 (26.3%) | 21 (28.4%) | 20 (24.7%) | 1.21 (0.59, 2.47) | 0.60 | |
Positive blood culture | 10 (6.4%) | 4 (5.4%) | 6 (7.6%) | 0.69 (0.19, 2.57) | 0.58 | |